Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Medroxyprogesterone for Corneal Healing After PRK
NCT05973253Phase 3Completed
- Start
- Apr 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of medroxyprogesterone acetate in Corneal epithelial defect (2 arms). Primary endpoint: Size of the corneal epithelial defect at Day 5. Started Apr 2023; status: completed.
02
Drugs
medroxyprogesterone acetate
03
Conditions
Corneal epithelial defect
Beyond the preview
Go deeper on NCT05973253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05973253.